MarginsXMarginsX
Home › Markets › Health Care › BMY

Bristol-Myers Squibb Company (BMY)

BMY trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$62.93
-0.79% on the day
Market cap
$128.6B
Large cap
Revenue · 2025
$48.2B
-0.2% on 2024
Net income · 2025
$7.1B
14.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/0000014272-26-000004-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBMY on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000014272
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$48.2B
Net income$7.1B
Operating incomeNot in SEC XBRL data
Net margin14.6%
Operating marginOperating income not reported
Revenue growth-0.2%
Cash$10.2B
Total assets$90.0B
P/E (computed)18.2×
P/S (computed)2.7×

Warning signs

Cash runway
Cash-flow positive
$9.6B cash at September 30, 2026
Share count, 1 year
+0.4%
2025-10-23 to 2026-10-21 · +0.5% over 3 years
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
-$2.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-29
Cash and burn$9.6B cash; operating cash flow $2.7B a quarter.Report 2026-09-30
Shares outstanding2,044,085,831 (2026-10-21); 2,035,753,027 a year earlier; 2,034,757,742 three years earlier.Cover page 2026-10-21
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2025-05-15
AuditorDeloitte & Touche LLP, Morristown, New Jersey, United StatesPCAOB Form AP 2026-02-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $2.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$13.1B$2.2B$4.2B$9.6B$43.6B$50.0B10-Q 2026-10-29
Q2 2026
2026-06-30
$13.0B$3.3B$3.4B$8.7B$43.9B$49.2B10-Q 2026-07-30
Q1 2026
2026-03-31
$11.5B$2.7B$1.1B$9.6B$46.4B$48.5B10-Q 2026-04-30
Q4 2025
2025-12-31
$12.5B$1.1B$2.0B$10.2B$47.1B$48.2B10-K 2026-02-11
Q3 2025
2025-09-30
$12.2B$2.2B$6.3B$15.7B$53.2B$48.0B10-Q 2026-10-29
Q2 2025
2025-06-30
$12.3B$1.3B$3.9B$12.6B$53.7B$47.7B10-Q 2026-07-30
Q1 2025
2025-03-31
$11.2B$2.5B$2.0B$10.9B$53.1B$47.6B10-Q 2026-04-30
Q4 2024
2024-12-31
$12.3B$72.0M$4.4B$10.3B$51.5B$48.3B10-K 2026-02-11

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-11-07
Latest annual report10-K2026-02-11
Latest quarterly / interim10-Q2026-10-29
Latest current report8-K2026-10-29
Latest proxyDEFA14A2026-04-17

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.1%
1 month+11.9%
3 months-1.9%
Year to date+17.6%
1 year+30.4%
From 52-week high-6.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
VRTXVertex Pharmaceuticals Incorporated$537.79-0.15%$136.4B
SNYSanofi ADS$48.39+0.04%$118.0B
GSKGSK plc$50.41-0.08%$102.0B
PFEPfizer Inc.$28.86-0.10%$164.5B
REGNRegeneron Pharmaceuticals Inc.$952.40-0.32%$98.5B
NVONovo Nordisk A/S$41.60-0.07%$184.2B
ABTAbbott Laboratories$107.45-0.99%$186.1B
TAKTakeda Pharmaceutical Company Limited$21.59+0.75%$68.2B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier